Physician profile
Alan Vu
NPI 1063432003
$1,299.83
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $355 · 2021: $366 · 2022: $88.57.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $428.86 | 2019-2020 | |
| Abbvie INC. | $311.87 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.58 | 2019-2021 | |
| Lundbeck LLC | $83.11 | 2019-2020 | |
| Adlon Therapeutics L.P. | $79.26 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $58.52 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $49.43 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $41.28 | 2019 | |
| Neurocrine Biosciences, INC. | $40.45 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $24.57 | 2019 | |
| Ethicon INC. | $23.27 | 2022 | |
| Merck Sharp & Dohme LLC | $18.84 | 2021 | |
| Eisai INC. | $17.22 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.68 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.